Sandoz, the global leader in biosimilars, announced it has initiated a Phase III clinical trial with its biosimilar version of adalimumab (AbbVie’s HUMIRA®) – the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn’s disease. ...
Read more